Growth Hormone Secretagogues

GHRP-2

Also known as Growth Hormone Releasing Peptide-2 · Pralmorelin · KP-102

Emerging researchSubcutaneous injectionIntravenous (research/diagnostic)Not FDA-approved in the US; approved in Japan as a diagnostic agent for growth-hormone deficiency. Not established as a permitted bulk substance for US compounding. Prohibited in sport (WADA, growth hormone secretagogues, S2).

GHRP-2 (pralmorelin) is a synthetic hexapeptide growth hormone secretagogue that activates the ghrelin receptor (GHS-R1a) to drive growth-hormone secretion, and is described in the literature as comparatively potent among the GHRPs. Alongside its growth-hormone effect it produces mild increases in prolactin, ACTH, and cortisol, and it can stimulate appetite. It is approved in Japan as a diagnostic agent for growth-hormone deficiency but is not approved in the US.

Studied / used for

Used in protocols for diagnostic evaluation of growth hormone secretion (approved indication in Japan)
Studied for stimulation of growth hormone release
Investigated for appetite stimulation

Commonly reported side effects

Injection-site reactions
Increased appetite
Mild rises in cortisol, ACTH, and prolactin
Flushing
Headache
Fluid retention

Emerging research. Active research; human evidence still developing. This reflects the strength of the research base, not effectiveness or a recommendation.

Not medical advice.

This is an educational reference. Peptalk does not recommend, prescribe, endorse, or rate any compound, and provides no dosing information. Do not start, stop, or change any peptide, hormone, supplement, or therapy based on this page. All clinical decisions must be made with your licensed healthcare provider.

← Back to all compounds